Viking Therapeutics, Inc.

NASDAQ:VKTX

Biotechnology

Healthcare
$26.17 +1.06%

+$0.32 today

Market cap
$3.34B
Beta
0.68
P/E (TTM)
-7.5
EPS (TTM)
-$4.09
52W Low $22.96High $43.15

Volume 2.87M

Average 2.20M

VKTX Financing Cash Flow

Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.

Viking Therapeutics, Inc.NASDAQ: VKTX

Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026

Financing cash flow growth accelerates

Q2 FY2026 financing cash flow of $23.59M rose 4552.1% year over year, ahead of the +2441.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 95.3% from the prior quarter. Over 3 fiscal years it compounded at +163.8% a year.

Context

  • Financing cash flow increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +4552.1% holds above the trailing-twelve-month pace of +2441.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$23.59M+95.3% QoQ
Last fiscal yearDec 2025
$76.44M-87.5% YoY
LTMJun 2026
$111.25M+2441.0% YoY
Financing Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4552.1%——
1 year-87.5%——
3-year CAGR+163.8%——
5-year CAGR——
10-year CAGR——

Financing Cash Flow history

USD · from the cash flow

Latest · FY2025
76.44M USD
Year-over-year change
-87.5%
4-year CAGR
+82.6%

Financing Cash Flow vs competitors

How VKTX compares with its peers on the latest reported figures

  • VKTX's LTM Jun 2026 financing cash flow of $111.25M is the 4th largest of the 7 companies compared; the peer median is $135.37M.
  • Its year-over-year change of +2441.0% is the 2nd highest of 6, against a peer median of +0.4%.
  • Over three fiscal years its annual growth of +163.8% compares with a peer median of -6.5%.
VKTX Competitors Peer median
Financing Cash Flow for VKTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KLRAKailera Therapeutics, Inc.FY2025$598.66M ———
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$251.04M +567.4%-6.5%19.6%
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$189.81M +0.4%+60.3%—
VKTXViking Therapeutics, Inc.LTM Jun 2026$111.25M +2441.0%+163.8%—
SEPNSepterna, Inc.LTM Sep 2026$80.93M -73.5%-61.7%84.1%
VTVTvTv Therapeutics Inc.LTM Mar 2026$77.44M +3044.2%+76.9%210.2%
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$41.68M -91.1%-57.8%585.3%
Peer median (excluding VKTX) $135.37M+0.4%-6.5%147.1%

Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(54.99M)(68.87M)(85.9M)(109.96M)(359.64M)
Depreciation & Amortization296K291K292K346K431K
Deferred Income Tax00000
Stock-Based Compensation6.1M8.67M16.75M29.71M40.82M
Change in Working Capital(2.93M)10.19M3.55M9.36M48.98M
Accounts Receivables1.18M614K321K1.2M5.08M
Inventory00000
Accounts Payables(2.54M)7.09M(1.02M)2.3M43.44M
Other Working Capital(1.56M)2.49M4.25M5.86M464K
Other Non-Cash Items3.94M1.32M(8.07M)(17.25M)(9.27M)
Operating Cash Flow(47.59M)(48.4M)(73.38M)(87.79M)(278.69M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments(168.02M)(121.43M)(478.3M)(1.11B)(418.04M)
Sales of Investments205.98M176.18M299.22M560M759.43M
Other Investing Activities054.75K000
Investing Cash Flow37.96M54.75M(179.09M)(553.37M)341.39M
Debt Repayment00000
Common Stock Issued7.59M0269.76M597.09M2.49M
Common Stock Repurchased0(6.8M)000
Dividends Paid00000
Other Financing Activities(707K)12.49M1.62M15.37M73.95M
Financing Cash Flow6.88M4.16M271.38M612.46M76.44M
Effect of Forex Changes0(258K)(30K)(148K)(8K)
Net Change in Cash(2.75M)10.26M18.88M(28.84M)139.13M
Free Cash Flow(47.59M)(48.4M)(73.38M)(87.79M)(278.69M)

Viking Therapeutics, Inc.

NASDAQ:VKTX

Intrinsic Alpha fair value

Locked

Current Price

$26.17

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.